Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in West Chester, PA, US. The stock last traded at $5.10, down 2.30% on the session, giving a market capitalisation of $87.6M. On trailing twelve-month figures it carries a trailing P/E of -2.93, a net margin of -102.8%. Its beta of 1.49 implies it has historically moved more than the broad market.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Verrica Pharmaceuticals Inc. is most often compared with the following Healthcare names: